The Effect and Mechanism of Improving Diabetes by Reconstruction Methods in Gastric Cancer Patients With DM Who Receive Surgical Treatment
Purpose:
- To investigate the effect of gastrectomy on remission of type 2 diabetes in patients
with gastric cancer and type 2 diabetes
- To investigate the mechanism of blood glucose alteration and intestinal hormonal
signaling by the reconstruction methods
- To evaluate the applicability and efficacy of Roux-en-Y gastrojejunostomy after
gastrectomy in gastric cancer patients with diabetes
Contents:
- Evaluation of the status of diabetes in gastric cancer patients with DM after
gastrectomy
- Comparison of two reconstruction types after gastrectomy Bypass duodenum and upper
jejunum: Roux-en-Y gastrojejunostomy Preservation of duodenal passage:
Gastroduodenostomy
- Analysis for biochemical markers reflecting diabetic status: fasting glucose,
postprandial 2h glucose, HbA1c, C-peptide, lipid profile
- Correlation of parameters associated with diabetes and GI hormones
- Measurement of GI hormones which have an effect on glucose tolerance
- Insulin, glucagon, IGF-1, GLP-1, Neuropeptide Y, Ghrelin, Leptin
- Correlation of reconstruction methods, parameters of diabetes and GI hormone
levels
- Evaluation of mechanism of Roux-en-Y gastrojejunostomy on controlling diabetes
- Evaluation of Feasibility of Roux-en-Y gastrojejunostomy in gastric cancer surgery in
patients with DM
- Degree of high blood glucose control, the amount of antidiabetic medication, costs
for DM treatment, quality of life assessment
- Analysis for the mechanism of gastrointestinal physiology to diabetes control
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Blood sugar stabilization after gastrectomy
By comparing the difference between fasting blood sugar and postprandial blood glucose, blood sugar stabilization after gastrectomy will be maesured.
three months after surgery
No
South Korea: Korea Food and Drug Administration (KFDA)
4-2011-0109
NCT01375738
July 2011
May 2014
Name | Location |
---|